The impact of modern antitumor drug therapy on oncoepidemiological indicators of cervical cancer in Krasnoyarsk Krai
https://doi.org/10.21518/ms2025-516
Abstract
Introduction. Cervical cancer, a malignant tumor that develops from the lining of the cervix. The main etiological factor in the development of this process is highly oncogenic strains of human papillomavirus type 16 and 18. Cervical cancer is 9th ranks in the prevalence of malignant neoplasms (MNEs) worldwide and 4th in the female population. In 2024, 426 new cases of cervical cancer were detected in the Krasnoyarsk Territory, which is 2.6% in the overall structure of oncological pathology (14th place) and 5.0% in the structure of female cancer incidence (6th place). In the structure of the stages of cervical cancer in the Krasnoyarsk Krai, the proportion of patients with I–II established stages of cervical cancer was 58.1% in 2022, in 2024 has increased to 66.0%. In a dynamic assessment of late stages of cervical cancer, namely III–IV, they accounted for a total of 31.0% in 2020, in 2022 this has increased to 41.9%, which makes this pathology even more actual in terms of diagnosis and choice of treatment approaches.
Aim. To evaluate the effectiveness of pembrolizumab immunotherapy in a patient with PD-L1-positive status, progressive cervical cancer after radical chemoradiotherapy and platinum-containing chemotherapy and its effect on the patient’s prognosis and epidemiological parameters of oncology.
Materials and methods. The analysis of GLOBOCAN data and reference books “Malignant neoplasms in Russia” is conducted. The results of the studies of KEYNOTE-158 and KEYNOTE-826 were used, as well as our own data obtained from the results of patient treatment.
Results. According to GLOBOCAN, cervical cancer ranks 4th among oncological diseases in women. In 2024 16.3 thousand new cases were identified in the Russian Federation. The Krasnoyarsk Krai demonstrates a high incidence rate. Modern treatment approaches, including the use of immunotherapy, have shown effectiveness and stabilization of the process after 19 courses.
Conclusions. Pembrolizumab immunotherapy is effective in patients with PD-L1-positive status, recurrent or metastatic cervical cancer, allows to achieve long-term stabilization and improve the prognosis.
About the Authors
D. V. Telyashkin
Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
Dmitry V. Telyashkin - Oncologist, Department of Oncology, Urogynecology, Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary.
16, 1st Smolenskaya St., Krasnoyarsk, 660133
Yu. V. Anzhiganova
Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
Yulia V. Anzhiganova - Head of Department, Oncologist, Department of Oncology, Urogynecology, Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary.
16, 1st Smolenskaya St., Krasnoyarsk, 660133
I. P. Safontsev
Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary; Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Ivan P. Safontsev - Cand. Sci. (Med.), Associate Professor, Department of Oncology and Radiation Therapy with a Postgraduate Course, Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky; Deputy Chief Physician for Organizational and Methodological Work, Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary.
1, Partizan Zheleznyak St., Krasnoyarsk, 660022; 16, 1st Smolenskaya St., Krasnoyarsk, 660133
E. V. Andriyanova
Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary
Russian Federation
Russian Federation
Elena V. Andriyanova - Physician-Statistician of the Organizational and Methodological Department, Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary.
16, 1st Smolenskaya St., Krasnoyarsk, 660133
R. A. Zukov
Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary; Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Ruslan A. Zukov - Dr. Sci. (Med.), Professor, Department of Oncology and Radiation Therapy with a Postgraduate Course, Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky; Chief Oncologist, Ministry of Health of Krasnoyarsk Krai, Chief Physician, Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary.
1, Partizan Zheleznyak St., Krasnoyarsk, 660022; 16, 1st Smolenskaya St., Krasnoyarsk, 660133
References
1. Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY et al. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russian Federation, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia. Vaccine. 2013;31(Suppl. 7):H46–H58. https://doi.org/10.1016/j.vaccine.2013.06.043.
2. Vinokurov MA, Leshkina GV, Akimkin VG. Cervical cancer in Russia. Мorbidity, mortality, and effectiveness of prevention measures: a retrospective epidemiological study. Medical Alphabet. 2024;(31):7–13. (In Russ.) Available at: https://www.med-alphabet.com/jour/article/view/4101.
3. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315–324. https://doi.org/10.1093/jnci/djq001.
4. Li XY, Li G, Gong TT, Lv JL, Gao C, Liu FH et al. Non-Genetic Factors and Risk of Cervical Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies. Int J Public Health. 2023;68:1605198. https://doi.org/10.3389/ijph.2023.1605198.
5. Mohammad N, Khan M, Maqsood M, Naseeb A. Cervical cancer demystified: exploring epidemiology, risk factors, screening, treatment modalities, preventive measures, and the role of artificial intelligence. Siberian Journal of Oncology. 2025;24(2):117–125. https://doi.org/10.21294/1814-4861-2025-24-2-117-125.
6. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ; 2021. 252 с. Режим доступа: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf.
7. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ; 2022. 252 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-v-rossii-v-2021-g_zabolevaemost-i-smertnost.pdf.
8. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). М.: МНИОИ; 2023. 275 с. Режим доступа: https://oms66.ru/upload/iblock/52d/6u9uo6ajmjooxfl8m738lck2qzog7lza/zno_2022.pdf.
9. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). М.: МНИОИ; 2024. 276 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdf.
10. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Злокачественные новообразования в России в 2024 году (заболеваемость и смертность). М.: МНИОИ; 2025. 178 с. Режим доступа: https://oncology.ru/service/statistics/malignant_tumors/2025.pdf.
11. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2020 году. М.: МНИОИ; 2021. 239 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2021/10/pomoshh-2020-el.-versiya.pdf.
12. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ; 2022. 239 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf.
13. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ; 2023. 254 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022-el.versiya_compressed.pdf.
14. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2023 году. М.: МНИОИ; 2024. 262 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2024/06/sop-2023-elektronnaya-versiya.pdf.
15. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2024 году. М.: МНИОИ; 2025. 275 с. Режим доступа: https://glavonco.ru/upload/onco2024.pdf.
16. Зуков РА, Сафонцев ИП, Клименок МП, Пермякова КД, Зырянова АЗ. Состояние онкологической помощи населению Красноярского края в 2022 году. Красноярск: КрасГМУ; 2023. 233 с.
17. Зуков РА, Сафонцев ИП, Наумова ТН, Пермякова КД, Зырянова АЗ. Состояние онкологической помощи населению Красноярского края в 2023 году. Красноярск: КрасГМУ; 2024. 235 с.
18. Зуков РА, Сафонцев ИП, Наумова ТН, Пермякова КД, Зырянова АЗ. Состояние онкологической помощи населению Красноярского края в 2024 году. Красноярск: КрасГМУ; 2025. 240 с. Режим доступа: https://kkkodkr.gosuslugi.ru/netcat_files/47/143/Sostoyanie_onkologicheskoy_pomoschi_naseleniyu_Krasnoyarskogo_kraya_v_2024_godu_na_sayt.pdf.
19. Prilepskaya VN, Mgeryan AN, Nazarova NM, Kostava MN. HPV-associated cervical diseases in women with autoimmune diseases: Vaccination. Akusherstvo i Ginekologiya (Russian Federation). 2016;(5):44–48. (In Russ.) https://doi.org/10.18565/aig.2016.5.44-48.
20. Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C et al. Cervical cancer: screening, diagnosis and staging. J BUON. 2016;21(2):320–325. Available at: https://www.jbuon.com/archive/21-2-320.pdf.
21. Khokhlova SV, Kolomiets LA, Kravets OA, Morkhov KYu, Nechushkina VM, Tyulandina AS, Urmancheeva AF. Practical recommendations for drug treatment of cervical cancer. Malignant Tumors. 2021;11(3s2-1):197–217. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-3s2-13.
22. Olyushina EM, Zavalishina LE, Andreeva YuYu, Kuznetsova OA, Moskvina LV, Frank GA. Predictive markers of immunotherapy in cervical cancer. Russian Journal of Archive of Pathology. 2023;85(5):5–12. (In Russ.) https://doi.org/10.17116/patol2023850515.
23. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37(17):1470–1478. https://doi.org/10.1200/JCO.18.01265.
24. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R et al. Pembrolisumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study. Gynecol Oncol. 2021;162(Suppl. 1):S27. https://doi.org/10.1016/S0090-8258(21)00696-X.
25. Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505–5511. https://doi.org/10.1200/JCO.23.00914.
26. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–1488. https://doi.org/10.1093/jnci/djq356.
27. Protasova AE, Strakh LV, Lando EI, Sidorkina EV. Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report. Journal of Modern Oncology. 2021;23(2):340–344. (In Russ.) https://doi.org/10.26442/18151434.2021.2.201009
28. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–891. https://doi.org/10.1002/ijc.22357.
29. Dugué PA, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013;13(1):29–42. https://doi.org/10.1586/era.12.159.
Review
For citations:
Telyashkin DV, Anzhiganova YV, Safontsev IP, Andriyanova EV, Zukov RA. The impact of modern antitumor drug therapy on oncoepidemiological indicators of cervical cancer in Krasnoyarsk Krai. Meditsinskiy sovet = Medical Council. 2025;(21):25-34. (In Russ.) https://doi.org/10.21518/ms2025-516
Views:
30
Email this article 